202 related articles for article (PubMed ID: 15660212)
21. [DNA vaccination].
Ihata A; Watabe S; Okuda K
Nihon Rinsho; 2006 Oct; 64(10):1865-9. PubMed ID: 17037361
[TBL] [Abstract][Full Text] [Related]
22. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
23. Vaccines in development against avian influenza.
Cox MM
Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
25. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
[TBL] [Abstract][Full Text] [Related]
26. Application of new vaccine technologies for the control of transboundary diseases.
Swayne DE
Dev Biol (Basel); 2004; 119():219-28. PubMed ID: 15742632
[TBL] [Abstract][Full Text] [Related]
27. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
28. Influenza A (H5N1) pandemic prototype vaccine Fluval.
Vajo Z
Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
[TBL] [Abstract][Full Text] [Related]
29. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.
Rimmelzwaan GF; Fouchier RA; Osterhaus AD
Curr Opin Biotechnol; 2007 Dec; 18(6):529-36. PubMed ID: 18083548
[TBL] [Abstract][Full Text] [Related]
30. [Vaccines: from seed virus to approval].
Bruhn C
Dtsch Med Wochenschr; 2009 Nov; 134(48):p44. PubMed ID: 19941270
[No Abstract] [Full Text] [Related]
31. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
[TBL] [Abstract][Full Text] [Related]
33. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
Bae K; Choi J; Jang Y; Ahn S; Hur B
Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
[TBL] [Abstract][Full Text] [Related]
34. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Barrett PN; Mundt W; Kistner O; Howard MK
Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
[TBL] [Abstract][Full Text] [Related]
35. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
Wu F; Yuan XY; Huang WS; Chen YH
Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
[TBL] [Abstract][Full Text] [Related]
36. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
37. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.
Heldens JG; Pouwels HG; Derks CG; Van de Zande SM; Hoeijmakers MJ
Vaccine; 2009 Sep; 27(40):5530-7. PubMed ID: 19607950
[TBL] [Abstract][Full Text] [Related]
38. Current status and progress of prepandemic and pandemic influenza vaccine development.
Leroux-Roels I; Leroux-Roels G
Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
[TBL] [Abstract][Full Text] [Related]
39. New vaccine approaches for seasonal and pandemic influenza.
Palache B
Vaccine; 2008 Nov; 26(49):6232-6. PubMed ID: 18674583
[TBL] [Abstract][Full Text] [Related]
40. Avian influenza vaccines and therapies for poultry.
Swayne DE
Comp Immunol Microbiol Infect Dis; 2009 Jul; 32(4):351-63. PubMed ID: 18442853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
